Phaseline

Targets › CSF1R

CSF1R (Macrophage colony-stimulating factor 1 receptor): drug programs, companies and trials

24 programs from 22 companies in 72 trials: 31 Phase 1, 29 Phase 2, 12 Phase 3; Oncology, Respiratory, Other; next expected readout Nov 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of pro-inflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in innate immunity and in…. (UniProt, P07333)

Open in Phaseline: the race on CSF1R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gossamer Bio USASeralutinib
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Macrophage colony stimulating factor receptor inhibitor
KIT, PDGFRB, PDGFRA, CSF1RPhase 3Pulmonary Arterial HypertensionDec 2026
Deciphera PharmaceuticalsVimseltinib (DCC-3014)
KIT/PDGFRA/CSF1R inhibitor
CSF1R, KIT, PDGFRAPhase 3Tenosynovial Giant Cell Tumor; Chronic Graft-Versus-Host Disease (cGVHD); Healthy Participants; Healthy Male Participants …Dec 2026
Xynomic PharmaceuticalsPazopanib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor
CSF1R, KIT, LCK, FGFR3, FGFR1Phase 3Renal Cell Carcinoma; Leiomyosarcoma or Carcinosarcoma; Soft Tissue Sarcoma; Rhabdomyosarcoma, Recurrent, Refractory …Dec 2026
IncyteAxatilimab
Macrophage colony stimulating factor receptor inhibitor
CSF1RPhase 3Chronic Graft-versus-host-disease; TNBC - Triple-Negative Breast Cancer; Hodgkin Lymphoma; Chronic Graft Versus Host Disease …Jan 2027
National Cancer Institute (NCI)Pazopanib Hydrochloride
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor
CSF1R, KIT, LCK, FGFR3, FGFR1Phase 3Clear Cell Renal Cell Carcinoma; Foregut Neuroendocrine Tumor; Solid NeoplasmFeb 2027
Daiichi SankyoPexidartinib
Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor
CSF1R, FLT3, KITPhase 3Tenosynovial Giant Cell Tumor; Neurofibroma, PlexiformMar 2027
Daiichi SankyoQuizartinib
Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor
CSF1R, FLT3, KIT, PDGFRB, PDGFRAPhase 3Leukemia; Acute Myeloid Leukemia; Hepatic Impairment; Acute Myeloid Leukemia, Adult …May 2027
Abbisko TherapeuticsPimicotinib capsule
CSF1R inhibitor
CSF1RPhase 3Tenosynovial Giant Cell Tumor; Healthy SubjectsJun 2028
SynOx TherapeuticsEmactuzumab
Macrophage colony stimulating factor receptor inhibitor
CSF1RPhase 3TGCTSep 2030
Syndax PharmaceuticalsAxatilimab
Macrophage colony stimulating factor receptor inhibitor
CSF1RPhase 2Idiopathic Pulmonary Fibrosis; Chronic Graft-versus-host-diseaseNov 2026
M.D. Anderson Cancer CenterSunitinib Malate
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Renal Cell Carcinoma; Malignant Neoplasms of Urinary Tract; Prostate CancerDec 2026
National Cancer Institute (NCI)Sunitinib Malate
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Advanced Lymphoma; Metastatic Pancreatic Neuroendocrine TumorDec 2026
Canadian Cancer Trials GroupSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Advanced Rare TumoursDec 2026
University of MiamiSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Gastrointestinal Stromal TumorsDec 2026
Sarcoma Alliance for Research through CollaborationSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Gastrointestinal Stromal TumorsJun 2027
American Society of Clinical OncologySunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Lymphoma, Non-HodgkinDec 2027
Bai-Rong XiaSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Ovary CancerDec 2027
Memorial Sloan Kettering Cancer CenterSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2OsteosarcomaMar 2028
Merck KGaAPimicotinib
CSF1R tyrosine kinase inhibitor
CSF1RPhase 2Tenosynovial Giant Cell TumorAug 2028
Turning Point Therapeuticselzovantinib (TPX-0022)
MET/CSF1R/SRC inhibitor
MET, CSF1R, SRCPhase 1Advanced Solid TumorMar 2027
State University of New York at BuffaloSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1Carcinoma, Renal CellJul 2027
University of Colorado, DenverSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1OsteosarcomaAug 2027
QurientAdrixetinib (Q702)
Axl/Mer/CSF1R selective tyrosine kinase inhibitor
AXL, MER, CSF1RPhase 1Esophageal Cancer; Chronic Graft-Versus-Host DiseaseDec 2027
Rabin Medical CenterSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1Solid Tumors Refractory to Standard TherapyJan 2028

Conditions

Chronic Graft-versus-host-disease (6) Acute Myeloid Leukemia (6) Tenosynovial Giant Cell Tumor (4) Renal Cell Carcinoma (3) Chronic Graft Versus Host Disease (2) Pulmonary Arterial Hypertension (2) Osteosarcoma (2) Gastrointestinal Stromal Tumors (2) Leiomyosarcoma or Carcinosarcoma (2) Idiopathic Pulmonary Fibrosis (1) Advanced Rare Tumours (1) TGCT (1)

Modalities

small molecule (18), antibody (3), mixed (3)

Companies

Daiichi Sankyo (2) National Cancer Institute (NCI) (2) Syndax Pharmaceuticals (1) Canadian Cancer Trials Group (1) SynOx Therapeutics (1) Incyte (1) Turning Point Therapeutics (1) Deciphera Pharmaceuticals (1) Merck KGaA (1) Gossamer Bio USA (1) Memorial Sloan Kettering Cancer Center (1) University of Colorado, Denver (1) Sarcoma Alliance for Research through Collaboration (1) Abbisko Therapeutics (1) State University of New York at Buffalo (1) Qurient (1) American Society of Clinical Oncology (1) University of Miami (1) Bai-Rong Xia (1) M.D. Anderson Cancer Center (1)

Related targets

KIT (17) PDGFRA (14) FLT3 (13) PDGFRB (13) LCK (2) FGFR3 (2) FGFR1 (2) MET (1) SRC (1) AXL (1) MER (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.